Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer

S. Tsujitani, A. Watanabe, Y. Abe, Yoshihiko Maehara, K. Sugimachi, N. Kaibara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Intraperitoneal chemotherapy has been attempted to treat peritoneal seeding in patients with gastric cancer. In this study, 13 patients with far advanced gastric cancer were given a complex chemotherapy regimen, cisplatin and etoposide, intraperitoneally during surgery. Cisplatin and etoposide was given 100 mg/body (58-90 mg/m2) and 200 mg/body (115-180 mg/m2), respectively, before closing the abdominal wall. There was one operative death who had an unresectable gastric cancer and died due to respiratory insufficiency, probably related to the drugs. There were no critical side effects due to the drugs among patients who underwent gastrectomy. Postoperative complications encountered were 2 cases of leukopenia, 2 of vomiting, 2 of renal impairment and 1 of liver dysfunction. These complications were transient and limited. The median survival duration was 7.0 months in this study. Thus, intraperitoneal cisplatin and etoposide should be examined for clinical use in larger scale trials.

Original languageEnglish
Pages (from-to)2497-2499
Number of pages3
JournalAnticancer research
Volume13
Issue number6 B
Publication statusPublished - Dec 1 1993

Fingerprint

Etoposide
Cisplatin
Stomach Neoplasms
Drug Therapy
Leukopenia
Abdominal Wall
Gastrectomy
Respiratory Insufficiency
Pharmaceutical Preparations
Vomiting
Liver Diseases
Kidney
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tsujitani, S., Watanabe, A., Abe, Y., Maehara, Y., Sugimachi, K., & Kaibara, N. (1993). Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer. Anticancer research, 13(6 B), 2497-2499.

Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer. / Tsujitani, S.; Watanabe, A.; Abe, Y.; Maehara, Yoshihiko; Sugimachi, K.; Kaibara, N.

In: Anticancer research, Vol. 13, No. 6 B, 01.12.1993, p. 2497-2499.

Research output: Contribution to journalArticle

Tsujitani, S, Watanabe, A, Abe, Y, Maehara, Y, Sugimachi, K & Kaibara, N 1993, 'Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer', Anticancer research, vol. 13, no. 6 B, pp. 2497-2499.
Tsujitani S, Watanabe A, Abe Y, Maehara Y, Sugimachi K, Kaibara N. Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer. Anticancer research. 1993 Dec 1;13(6 B):2497-2499.
Tsujitani, S. ; Watanabe, A. ; Abe, Y. ; Maehara, Yoshihiko ; Sugimachi, K. ; Kaibara, N. / Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer. In: Anticancer research. 1993 ; Vol. 13, No. 6 B. pp. 2497-2499.
@article{5d270d08b4b849efae1d2cafa7361a4a,
title = "Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer",
abstract = "Intraperitoneal chemotherapy has been attempted to treat peritoneal seeding in patients with gastric cancer. In this study, 13 patients with far advanced gastric cancer were given a complex chemotherapy regimen, cisplatin and etoposide, intraperitoneally during surgery. Cisplatin and etoposide was given 100 mg/body (58-90 mg/m2) and 200 mg/body (115-180 mg/m2), respectively, before closing the abdominal wall. There was one operative death who had an unresectable gastric cancer and died due to respiratory insufficiency, probably related to the drugs. There were no critical side effects due to the drugs among patients who underwent gastrectomy. Postoperative complications encountered were 2 cases of leukopenia, 2 of vomiting, 2 of renal impairment and 1 of liver dysfunction. These complications were transient and limited. The median survival duration was 7.0 months in this study. Thus, intraperitoneal cisplatin and etoposide should be examined for clinical use in larger scale trials.",
author = "S. Tsujitani and A. Watanabe and Y. Abe and Yoshihiko Maehara and K. Sugimachi and N. Kaibara",
year = "1993",
month = "12",
day = "1",
language = "English",
volume = "13",
pages = "2497--2499",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer

AU - Tsujitani, S.

AU - Watanabe, A.

AU - Abe, Y.

AU - Maehara, Yoshihiko

AU - Sugimachi, K.

AU - Kaibara, N.

PY - 1993/12/1

Y1 - 1993/12/1

N2 - Intraperitoneal chemotherapy has been attempted to treat peritoneal seeding in patients with gastric cancer. In this study, 13 patients with far advanced gastric cancer were given a complex chemotherapy regimen, cisplatin and etoposide, intraperitoneally during surgery. Cisplatin and etoposide was given 100 mg/body (58-90 mg/m2) and 200 mg/body (115-180 mg/m2), respectively, before closing the abdominal wall. There was one operative death who had an unresectable gastric cancer and died due to respiratory insufficiency, probably related to the drugs. There were no critical side effects due to the drugs among patients who underwent gastrectomy. Postoperative complications encountered were 2 cases of leukopenia, 2 of vomiting, 2 of renal impairment and 1 of liver dysfunction. These complications were transient and limited. The median survival duration was 7.0 months in this study. Thus, intraperitoneal cisplatin and etoposide should be examined for clinical use in larger scale trials.

AB - Intraperitoneal chemotherapy has been attempted to treat peritoneal seeding in patients with gastric cancer. In this study, 13 patients with far advanced gastric cancer were given a complex chemotherapy regimen, cisplatin and etoposide, intraperitoneally during surgery. Cisplatin and etoposide was given 100 mg/body (58-90 mg/m2) and 200 mg/body (115-180 mg/m2), respectively, before closing the abdominal wall. There was one operative death who had an unresectable gastric cancer and died due to respiratory insufficiency, probably related to the drugs. There were no critical side effects due to the drugs among patients who underwent gastrectomy. Postoperative complications encountered were 2 cases of leukopenia, 2 of vomiting, 2 of renal impairment and 1 of liver dysfunction. These complications were transient and limited. The median survival duration was 7.0 months in this study. Thus, intraperitoneal cisplatin and etoposide should be examined for clinical use in larger scale trials.

UR - http://www.scopus.com/inward/record.url?scp=0027811086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027811086&partnerID=8YFLogxK

M3 - Article

C2 - 8135489

AN - SCOPUS:0027811086

VL - 13

SP - 2497

EP - 2499

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -